Binimetinib, a Novel MEK1/2 Inhibitor, Exerts Anti-Leukemic Effects Under Inactive Status of PI3Kinase/Akt Pathway

International Journal of Hematology - Japan
doi 10.1007/s12185-019-02667-1
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Icaritin, a Novel FASN Inhibitor, Exerts Anti-Melanoma Activities Through IGF-1R/STAT3 Signaling

Oncotarget
Oncology
2016English

Combination of EGFR and MEK1/2 Inhibitor Shows Synergistic Effects by Suppressing EGFR/HER3-dependent AKT Activation in Human Gastric Cancer Cells

Molecular Cancer Therapeutics
Cancer ResearchOncology
2009English

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy--Response

Clinical Cancer Research
Cancer ResearchOncology
2016English

Exogenous Hydrogen Sulfide Exerts Proliferation, Anti-Apoptosis, Migration Effects and Accelerates Cell Cycle Progression in Multiple Myeloma Cells via Activating the Akt Pathway

Oncology Reports
MedicineCancer ResearchOncology
2016English

The Marine-Derived Kinase Inhibitor Fascaplysin Exerts Anti-Thrombotic Activity

Marine Drugs
Drug Discovery
2015English

Galangin Ameliorates Cardiac Remodeling via the MEK1/2-ERK1/2 and PI3K-AKT Pathways

Journal of Cellular Physiology
Clinical BiochemistryCell BiologyPhysiology
2019English

Sanbai Melon Seed Oil Exerts Its Protective Effects in a Diabetes Mellitus Model via the Akt/GSK-3β/Nrf2 Pathway

Journal of Diabetes Research
EndocrinologyMetabolismDiabetes
2019English

Antitumor Activities of JTP-74057 (GSK1120212), a Novel MEK1/2 Inhibitor, on Colorectal Cancer Cell Lines in Vitro and in Vivo

International Journal of Oncology
Cancer ResearchOncology
2011English

Status of PI3K/Akt/mTOR Pathway Inhibitors in Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy